Clinical trial · Interventional
Imiquimod 5% Cream for the Treatment of Periocular Basal Cell Carcinoma
NCT00803907CI-TRIAL-00007174ImiquimodunknownPhase 4ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study aimed to prove the efficacy and safety of the use of imiquimod 5% cream in the periorbital region.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Carcinoma, Basal Cell | Basal Cell Carcinoma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Imiquimod 5% cream | Drug | Imiquimod | ALIAS |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- nodular BCC of the eyelid
- description
- Patients with nodular BCC of the eyelid
- interventionNames
- Drug: Imiquimod 5% cream
Primary outcomes (1)
- measure
- post-treatment biopsy
- timeFrame
- post-treatment biopsy
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 90 Years
Show eligibility criteria text
Inclusion Criteria: * Patients whose injuries were confirmed by anatomical and pathological study (periocular superficial basal cell carcinoma). * Patients with clinical counter indication for reconstructive surgery (high surgical risk). * Patients who have refused a restorative surgery. (aesthetic reasons) * Patients who have signed the free and informed consent. Exclusion Criteria: * Patients who have a hypersensitivity reaction to the formula components. * Children under 12 years of age. * Pregnant and breastfeeding women. * Patients whose injury was not confirmed by anatomical and pathological study. * Individuals with previous autoimmune or inflammatory disease. * Patients who have refused to sign the free and informed term of consent.
References
Publications (1)
- DERIVEDde Macedo EM, Carneiro RC, de Lima PP, Silva BG, Matayoshi S. Imiquimod cream efficacy in the treatment of periocular nodular basal cell carcinoma: a non-randomized trial. BMC Ophthalmol. 2015 Apr 3;15:35. doi: 10.1186/s12886-015-0024-0. PMID 25885553